SCHEMBL6603543

SCHEMBL6603543

CCOc1cc(-c2ccccc2)nn1CCOc1cc(-c2ccsc2)ccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.36
TRPM4 Q8TD43 1/20 0.36
SLC6A9 P48067 1/20 0.36
HTR1A P08908 1/20 0.35
ADORA1 P30542 2/20 0.35
ADORA2B P29275 1/20 0.35
TP53 P04637 1/20 0.34
MDM2 Q00987 1/20 0.34
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CNR1 P21554 1/20 0.33
HTR2C P28335 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SLC16A3 O15427 1/20 0.33
SLC16A1 P53985 1/20 0.33
MCTS1 Q9ULC4 1/20 0.33
PDE6D O43924 1/20 0.33
PDE5A O76074 1/20 0.33
PDE6A P16499 1/20 0.33
PDE6G P18545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601388 0.93 CREBBP (0.38) ADORA2ATRPM4SLC6A9HTR1AADORA1
SCHEMBL6606052 0.86 HPGD (0.39) ADORA2ATRPM4SLC6A9HTR1AADORA1
SCHEMBL6601824 0.85 KDM4E (0.38) ADORA2ASLC6A9TP53MDM2POLB
SCHEMBL6601689 0.84 SCN9A (0.38) SLC6A9
SCHEMBL6612367 0.83 TP53 (0.42) TRPM4TP53MDM2POLBALDH1A1
SCHEMBL6606680 0.82 MAPT (0.37) ADORA2AADORA1TP53MDM2POLB
SCHEMBL6805998 0.82 HPGD (0.41) TP53MDM2POLBSMN1; SMN2HTR2C
SCHEMBL6602658 0.82 HPGD (0.42) TP53MDM2POLBSMN1; SMN2HTR2C
SCHEMBL6604092 0.81 HTR2C (0.35) TP53MDM2POLBSMN1; SMN2HTR2C
SCHEMBL6603641 0.81 KDM4E (0.38) ADORA1TP53MDM2POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 ADORA2A 3234/4885TRPM4 4733/4885SLC6A9 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.